Statins and prOgression of Coronary atheRosclerosis in melanomA Patients Treated With chEckpoint inhibitorS

Inclusion Criteria:

• Capable of providing informed consent and willing to adhere to all protocolrequirements

• patients aged > or equal to 40 years

• Histologically confirmed melanoma of any stage planned for, commenced, or completedtreatment with ICI

• having acceptable imaging quality deemed by the core laboratory

• Investigator believes that the participant is willing to adhere to all protocolrequirements, including returning for follow up CTCA.

Exclusion Criteria:

• Known clinically manifest cardiovascular disease

• Female participants must not be pregnant, breastfeeding or plan to become pregnantduring the study.

• Estimated glomerular filtration rate of <45 mL/min calculated using the ChronicKidney Disease Epidemiology Collaboration equation

• Severe liver disease or cirrhosis

• History of any other malignancy within the past 5 years in addition to melanoma withthe exception of non-melanoma skin cancers

• Prognostic factors associated with an expected survival less than 18 months atInvestigators' discretion (e.g. unresectable brain metastases)

• Evidence of any other clinically significant non-cardiac disease or condition that,in the opinion of the Investigator, would preclude participation in the study

• Major allergy to iodine

• Participation in another clinical trial that does not allow participation inmultiple trials at the same time